Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
More than half of patients treated with mitomycin experienced complete tumor remission.
Novel antibody-drug conjugate shrank tumors in more than 40% of people previously treated with immunotherapy.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
More than 40% of people treated with enfortumab vedotin experienced complete or partial remission.
Requires use of diagnostic tests for PD-L1 levels in tumor tissue from bladder cancer patients.
Decreased survival seen in some metastatic bladder cancer patients treated with pembrolizumab or atezolizumab monotherapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.